Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02186 LUYE PHARMA
RTNominal down3.620 -0.040 (-1.093%)
Others

11/06/2021 10:19

Luye Pharma (02186) gets marketing authorization application

[ET Net News Agency, 11 June 2021] Luye Pharma Group Ltd. (02186) said the marketing
authorization application for the Class 1 new chemical entity (NCE) product Anshufaxine
Hydrochloride Extended-release Tablets (LY03005) under development by the group has been
accepted by the Centre for Drug Evaluation of the National Medical Products Administration
in the People's Republic of China.
LY03005 is a new antidepressant agent developed by the new therapeutic entity/new
chemical entity (NTE/NCE) technology platform of the group. Studies reveal that
Anshufaxine is a serotonin (5-HT)-norepinephrine (NE)-dopamine (DA) reuptake inhibitor
(SNDRIs). (RC)

Remark: Real time quote last updated: 25/01/2022 10:03
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.